Engineered IL-7 Receptor Enhances the Therapeutic Effect of AXL-CAR-T Cells on Triple-Negative Breast Cancer

Figure 1

Screening of target cells and the construction of engineered T cells. (a) The expression levels of AXL in target cells detected by flow cytometry. (b) Schematic diagram of C7R, AXL-CAR, and AXL-CAR.C7R. (c) Working principle diagram of C7R. (d) CD3ζ and CD34 were detected by immunoblot assay. Exogenous CD3ζ was presented at 70 kDa only in the lanes of CAR-T cells, and endogenous CD3ζ was presented at 17 kDa in the lanes of control T cells and CAR-T cells. CD34 is presented in cells containing C7R. GAPDH is used as an internal standard. (e) The transfection efficiency of engineered T cells was determined by GFP expression in T cells using flow cytometry.

(a)

(b)

(c)

(d)

(e)